Dr. Freed has over 20 years of drug development experience across numerous therapeutic areas with drug development experience ranging from Phase I through IV. Prior to co-founding Civitas, he served as chief medical officer at Adnexus Therapeutics (acquired by BMS) and at Vitae Pharmaceuticals. Before that he spent nearly 14 years at SmithKline Beecham and GlaxoSmithKline serving numerous roles including vice president, clinical development and medical affairs in the metabolism therapeutic area. Dr. Freed has consulted extensively and served on the Board of InteKrin Therapeutics. A fellow of the American College of Physicians, he received his Doctor of Medicine from Pennsylvania State University’s College of Medicine and graduated magna cum laude with a Bachelor of Arts with Distinction in Biology from the University of Delaware. He is board certified in internal medicine, nephrology and clinical pharmacology, having performed his internal medicine residency and nephrology fellowship at Temple University Hospital and Yale-New Haven Hospital, respectively.